Definition of short stature.
Short stature is defined as individuals of the same race, sex and age whose height is less than 2 standard deviations (-2SD) from the mean height of the normal population or less than the 3rd percentile (-1.88SD) in similar life circumstances, some of which are normal physiological variants, and for proper diagnosis, appropriate clinical observations and laboratory tests must be performed in children with growth retardation.
Etiology.
There are many factors leading to short stature, including many interactions, and there are also many diseases leading to short stature whose mechanisms have not been elucidated so far
Diagnosis.
A comprehensive examination must be performed in children with short stature to identify the cause for treatment.
I. Medical history
The mother’s pregnancy, the birth history, the length and weight of the child, the growth history, the parents’ puberty and the short stature in the family, etc. should be carefully investigated.
Physical examination
In addition to the routine physical examination, the following items should be measured and recorded correctly.
① Current height and weight measurement values and percentile;
②The annual growth rate of height (at least 3 months of observation);
③Target height measured from the height of the parents;
④BMI value;
⑤ Sexual development staging.
III. Laboratory tests
Blood and urine tests and liver and kidney function tests should be routinely performed; blood gas and electrolyte analysis are recommended for suspected renal tubular toxicity; karyotype analysis is required for girls; to exclude subclinical hypothyroidism, thyroid hormone levels should be routinely tested.
Bone Age (BA) is a good indicator to assess the development of an organism. Bone age is the maturity of bone at each age, and is determined by observing the growth and development of each ossification center on ortho-X-rays of the left wrist, palm and finger bones. The most used methods at home and abroad are the G-P method (Greulich & Pyle) and the TW3 method (Tanner-Whitehouse), and the G-P method is mostly used in our clinic. Under normal circumstances, the difference between bone age and actual age should be between ±1 year, and being too far behind or too far ahead is considered abnormal.
3.Special examination
(1) Indications for special examination ① those whose height is lower than the normal reference value minus 2SD (or lower than the 3rd percentile); ② those whose bone age is lower than the actual age by more than 2 years; ③ those whose height growth rate is below the 25th percentile (according to bone age), i.e. <7CM/rh for children <2 years old; ④ those who have clinical symptoms of endocrine disorder or dysmorphic syndrome; ⑤ those who need pituitary function examination for other reasons .
(2) Growth hormone-insulin-like growth factor-1 axis (GH-IGF-1) function determination The physiological screening tests used in the past, such as exercise and sleep, are rarely used now, and most of them directly use drug stimulation tests (see Table 2).
(3) Measurement of insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) The serum concentrations of both increase with age and development, and are related to nutrition and other factors, so each laboratory should establish its own reference data.
(4) IGF-1 production test For children with suspected GH resistance (Laron syndrome), this test can be used to detect GH receptor function. Method 1: 0.075-0.15 U/(kg・d) of rhGH was injected subcutaneously every night for 1 week, and blood samples were collected once before the injection and once on the 5th and 8th day after the injection to determine IGF-1; Method 2: 0.3 U/(kg・d) of rhGH was injected subcutaneously every night for 4 days, and blood samples were collected once before the injection and once after the last injection to determine IGF-1. The serum IGF-1 of normal individuals will increase more than 3 times its basal value after injection, or reach the normal value corresponding to their age.
(5) Testing of other endocrine hormones Depending on the clinical manifestations of the child, other hormone choices may be tested as needed
(6) Imaging of hypothalamus and pituitary gland MRI should be performed in children with short stature to exclude the possibility of congenital developmental abnormalities or tumors.
(7) Karyotype analysis Karyotype analysis should be performed in all children suspected of having chromosomal aberrations.
Differential diagnosis:
Based on medical history and physical examination, it is easy to identify short stature caused by malnutrition, psychosomatic family idiopathic short stature, small for gestational age, chronic systemic diseases, etc. Common causes of short stature should be identified, such as: chondrodysplasia, hypothyroidism, delayed somatic puberty; clinical attention should also be paid to the possibility of certain syndromes In addition, some syndromes such as Prader-Willi syndrome, Silver-Russeli syndrome, Noonan syndrome, etc. should be identified.
Treatment:
1, treatment measures for children with short stature depend on their etiology Psycho-psychological, renal tubular acidosis and other children with related factors are eliminated, their height growth rate is seen to increase, daily nutrition and sleep security are closely related to normal growth and development.
2.Growth hormone With the accumulation of experience in the clinical application of recombinant human growth hormone (rhGH), the number of diseases approved for treatment with rhGH has gradually increased. Prader-Willi syndrome (2000), small for gestational age (2001), and idiopathic short stature (2003).
Since most children younger than gestational age show catch-up growth in the first 2-3 years of life and can reach a growth curve proportional to their target height, they should be regularly followed up and observed. In 2003, the FDA approved GH for idiopathic short stature, i.e.: (i) those with unknown causes of non-GH deficiency; (ii) those whose height is lower than the normal reference value of 2.25 SD or more for children of the same sex and age; and (iii) those whose lifetime height in adulthood is expected to be below -2SDS.
(1) Dosage form Domestic options include rhGH powder and water, with the latter having a slightly better growth effect.
(2) Dose The dose of growth hormone has a wide range and should be individually adjusted according to the need and the observed efficacy. At present, the commonly used dose in China is 0.1-0.15IU/kg・d, 0.23-0.35mg/kg per week; for children with pubertal development, children with Turner, children younger than fetal age, children with idiopathic short stature and some children with partial growth hormone deficiency, the applied dose is 0.15-0.20IU/(K.d), 0.35-0.46(J.K) per week (Note: WHO labeled growth hormone 1J=30). WHO labeled growth hormone 1J=30U)
(3) Usage: 1 subcutaneous injection every night before bedtime, the usual injection site is the outer and anterior flank of the middle 1/2 of the thigh, and the injection site should be changed each time to avoid the degeneration of subcutaneous tissue due to repetition within a short period of time.
(4) Course of treatment: The course of growth hormone treatment for short stature depends on the need, usually should not be shorter than 1-2 years, too short when the child’s benefit to its lifelong high role is not great.
(5) Side effects: The common side effects are.
① Hypothyroidism: Occurs every 2-3 months after the start of injection and can be corrected by giving L-thyroxine tablets as needed;
② Altered glucose metabolism: Long-term use of large amounts of growth hormone may cause insulin resistance to occur in children. Fasting blood glucose and insulin levels may rise, but rarely exceed the normal high limit, and may recover after several months of growth hormone discontinuation;
(iii) Idiopathic benign intracranial pressure elevation: Growth hormone can cause nadir and water retention, and individual patients may experience idiopathic intracranial pressure elevation, peripheral edema and blood pressure elevation, which mostly occurs in children with chronic renal failure, Turner syndrome and GH deficiency-induced growth disorders;
④Antibody production: Due to the continuous improvement of preparation purity, the rate of antibody production has been reduced, and even less for aqueous preparations;
⑤ Femoral head slippage and necrosis: because the growth of bones is accelerated and muscle strength is increased after treatment, the increased movement is likely to cause femoral head slippage, aseptic necrosis and lameness, and also knee and hip pain, which is externally rotated pathology, GH can be temporarily discontinued and treated with vitamin D and calcium tablets
(6) Local redness or rash of injection: usually disappears within a few days and can be continued, but it is now rare.
(7) The possibility of tumor induction: International organizations have conducted relevant research studies, and according to a large amount of epidemiological data from academic institutions such as the National Cooperative Growth Group and the Center for Drug Therapy Research, including a comprehensive analysis of population information such as age, gender and race of tumor patients, the results show that GH treatment does not increase the risk of leukemia occurrence and tumor recurrence in children without the presence of potential tumor risk factors, but for However, for those who have had tumor, have family genetic tendency of tumor occurrence, malformation syndrome, caution is needed when long-term supraphysiological dose of GH is applied, and serum IGF-1 level should be closely monitored during treatment, and those who exceed the normal reference value +2SD should be temporarily discontinued.
3. Other drugs.
①The supplementation of calcium and trace elements should be paid attention to during the course of treatment for the bone growth required;
②Anabolic hormone: often used with growth hormone to treat Turner syndrome, most domestic use stanozolol (Conilon), the common dose of 0.025-0.05J/(K.d) need to pay attention to the growth of bone age;
③ IGF-1 gonadal axis inhibition (GnRHa), aromatase inhibitors (Letrozole, Letrozole) have also been used to treat short stature, but there is not enough information to analyze in China, so it is not recommended for routine application.